DDW Editor Reece Armstrong speaks to Michael Wyand, Chief Executive Officer/Director, Oxeia Biopharmaceuticals about the development of the company’s treatment for concussion (OXE103) and the current lack of effective therapies for brain injuries. RA: Tell us how OXE103 works? MW: OXE103 (ghrelin) is a 28 amino acid neuro-peptide hormone that crosses the blood brain […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!